Name: 4th Inflammatory Bowel Disease Horizons (IBDH) Annual Seattle Conference
Start: 2019-03-02
End: 2019-03-02
Location: Bell Harbor International Conference Center

OVERVIEW

4th Inflammatory Bowel Disease Horizons (IBDH) Annual Seattle Conference is organized by Inflammatory Bowel Disease Horizons (IBDH) and will be held on Mar 02, 2019 at Bell Harbor International Conference Center, Seattle, Washington, United States of America. This CME Conference has been approved for a maximum of 6 AMA PRA Category 1 Credits™.

Target Audience :
The target audience are healthcare providers caring for IBD patients: adult and pediatric gastroenterologists, advanced registered nurse practitioners and physician assistants, medical staff, dietician, surgeons, and pharmacists.

Course Description :
The management of IBD is highly dynamic with extensive, cutting-edge information deriving from a wealth of ongoing scientific, clinical, and therapeutic research programs. The mission of IBD Horizons is to provide healthcare providers the opportunity to enhance their clinical knowledge by providing the most up-to-date information regarding the management of IBD. Cutting edge topics delivered by respected educators/leaders in the IBD field, as well as opportunities for interaction between the presenters and participants have been designed into the educational program.

Course Topics :

• Personalized Treatment of IBD

• Management of Proctosigmoiditis Beyond Mesalamine

• Management of Preclinical & Mild Crohn’s Ileitis

• Choosing an IBD Therapy from the Expanding Options

• Management of Severe Refractory Ulcerative Colitis

• Medical and Surgical Management of Perianal Crohn’s Disease

• Surgical and Medical Management of the Failing Pouch

• Treatment of the Pregnant IBD Patient with Active Disease

Course Objectives :

After completion of this activity, participants will be able to:

• Assess the benefits and limitations of personalized medicine in the context of managing patients with IBD.

• List factors that should be evaluated in the selection of therapy for patients with Crohn’s disease and how to align these with the patients’ treatment goals.

• List predictors of suboptimal response to medical therapies and describe approaches for monitoring and predicting treatment response in patients with CD.

• Identify the most promising molecules in late-stage clinical development, with an emphasis on immunological targets and pharmacological properties.

• Identify clinical gaps/controversies and apply evidence-based medical management of mild-to-moderate ulcerative colitis to individualize patient care.

• Incorporate evidence-based treatment strategies to optimize outcomes in patients with moderate-to-severe UC who are sub-optimally controlled and/or considered to be treatment failures.

• Examine the current clinical practice of post-operative management of Crohn’s disease and apply best practice medical management treatment strategies.

• Apply the most recent evidence regarding family planning and the reproductive safety of IBD medications when counseling patients with IBD who are considering conception or who are pregnant.